2658-6533Research Results in Biomedicine2658-653310.18413/2658-6533-2024-10-2-0-33420Genetics<strong>Polymorphism in the matrix metallopeptidase genes is associated with coronary artery disease risk with concomitant metabolic syndrome</strong><br /> &nbsp;<strong>Polymorphism in the matrix metallopeptidase genes is associated with coronary artery disease risk with concomitant metabolic syndrome</strong><br /> &nbsp;PonasenkoAnastasia V.PonasenkoAnastasia V.ponaav@kemcardio.ruSinitskayaAnna V.SinitskayaAnna V.cepoav1991@gmail.comKhutornayaMaria V.KhutornayaMaria V.masha_hut@mail.ruSinitskyMaxim Yu.SinitskyMaxim Yu.max-sinitsky@rambler.ruAsanovMaxim A.AsanovMaxim A.asmaks988@gmail.comPoddubnyakAlena O.PoddubnyakAlena O.alyona.poddubnyak@gmail.com202410200

Background: Metabolic syndrome (MS) and its components are the reasons of the development and progression of cardiovascular diseases. Nowadays, the association between coronary artery disease and MS remains ambiguous. The central role of matrix metallopeptidases (MMP) in the metabolism of connective tissue proteins, cell matrix remodeling, tissue repair and other complex biochemical processes has been shown, which implies their involvement in the pathogenesis of cardiovascular diseases. The aim of the study: To study the associations of polymorphic variants in the MMP genes with the risk of stable coronary artery disease with concomitant metabolic syndrome. Materials and methods: 170 patients with stable coronary artery disease concomitant with a visceral type of obesity in combination with two or more pathological conditions (elevated serum blood glucose level, elevated serum blood cholesterol level, hypertension) were included in the case group. Conditionally healthy volunteers (n=182) were recruited in the control group. Genotyping of five polymorphic sites in the four genes MMP1 (rs514921), MMP3 (rs6796620 and rs626750), MMP9 (rs17576) and TIMP2 (rs2277698) was performed by real-time PCR. The serum blood level of MMP was measured by ELISA. Gene-gene interactions were analyzed using MDR v.3.0.2 software. Results: The frequency of heterozygous C/T genotype in the MMP3 gene (rs626750) was higher in the control group (37.90%) compared to the case group (23.20%), which indicates its protective effect on the risk of coronary artery disease with concomitant metabolic syndrome (OR=0.47, 95%CI 0.29-0.75). 2.6-fold increased risk of coronary artery disease with concomitant metabolic syndrome was demonstrated for carriers of the A/G genotype in the TIMP2 gene (rs2277698) according to the codominant inheritance model. We found no associations of polymorphic variants in the MMP1 (rs514921), MMP3 (rs626750), MMP9 (rs17576) and TIMP2 (rs2277698) genes with the serum blood level of MMP, as well as their inhibitors. Four-loci model of gene-gene interactions (MMP9 (rs17576) &ndash; MMP3 (rs626750) &ndash; MMP1 (rs514921) &ndash; TIMP2 (rs2277698)) characterized by high sensitivity, specificity and risk effect to the coronary artery disease with concomitant metabolic syndrome development was discovered. Conclusion: This study revealed the association of polymorphic variants in the MMP genes and their inhibitors with the risk of coronary artery disease with concomitant metabolic syndrome. In addition, a four-locus model of intergenic interactions with high sensitivity and specificity was obtained

Background: Metabolic syndrome (MS) and its components are the reasons of the development and progression of cardiovascular diseases. Nowadays, the association between coronary artery disease and MS remains ambiguous. The central role of matrix metallopeptidases (MMP) in the metabolism of connective tissue proteins, cell matrix remodeling, tissue repair and other complex biochemical processes has been shown, which implies their involvement in the pathogenesis of cardiovascular diseases. The aim of the study: To study the associations of polymorphic variants in the MMP genes with the risk of stable coronary artery disease with concomitant metabolic syndrome. Materials and methods: 170 patients with stable coronary artery disease concomitant with a visceral type of obesity in combination with two or more pathological conditions (elevated serum blood glucose level, elevated serum blood cholesterol level, hypertension) were included in the case group. Conditionally healthy volunteers (n=182) were recruited in the control group. Genotyping of five polymorphic sites in the four genes MMP1 (rs514921), MMP3 (rs6796620 and rs626750), MMP9 (rs17576) and TIMP2 (rs2277698) was performed by real-time PCR. The serum blood level of MMP was measured by ELISA. Gene-gene interactions were analyzed using MDR v.3.0.2 software. Results: The frequency of heterozygous C/T genotype in the MMP3 gene (rs626750) was higher in the control group (37.90%) compared to the case group (23.20%), which indicates its protective effect on the risk of coronary artery disease with concomitant metabolic syndrome (OR=0.47, 95%CI 0.29-0.75). 2.6-fold increased risk of coronary artery disease with concomitant metabolic syndrome was demonstrated for carriers of the A/G genotype in the TIMP2 gene (rs2277698) according to the codominant inheritance model. We found no associations of polymorphic variants in the MMP1 (rs514921), MMP3 (rs626750), MMP9 (rs17576) and TIMP2 (rs2277698) genes with the serum blood level of MMP, as well as their inhibitors. Four-loci model of gene-gene interactions (MMP9 (rs17576) &ndash; MMP3 (rs626750) &ndash; MMP1 (rs514921) &ndash; TIMP2 (rs2277698)) characterized by high sensitivity, specificity and risk effect to the coronary artery disease with concomitant metabolic syndrome development was discovered. Conclusion: This study revealed the association of polymorphic variants in the MMP genes and their inhibitors with the risk of coronary artery disease with concomitant metabolic syndrome. In addition, a four-locus model of intergenic interactions with high sensitivity and specificity was obtained

coronary artery diseasemetabolic syndromeMMP1MPP3MPP9TIMP2coronary artery diseasemetabolic syndromeMMP1MPP3MPP9TIMP2Список литературыRotar OP, Kolesova EP, Moguchaya EV, et al. Genetic markers of the metabolic syndrome in the Russian population (based on the ESSE-RF study). Arterial Hypertension. 2019;25(5):467-477. Russian. DOI: https://doi.org/10.18705/1607-419X-2019-25-5-467-477Jing Z, Liu L, Shi Y, et al. Association of coronary artery disease and metabolic syndrome: usefulness of serum metabolomics approach. Frontiers in Endocrinology. 2021;12:692893. DOI: https://doi.org/10.3389/fendo.2021.692893de Almeida LGN, Thode H, Eslambolchi Y, et al. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacological Reviews. 2022;74(3):714-770. DOI: https://doi.org/10.1124/pharmrev.121.000349Marino-Puertas L, Goulas T, Gomis-Ruth FX. Matrix metalloproteinases outside vertebrates. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2017;1864(11A):2026-2035. DOI: https://doi.org/10.1016/j.bbamcr.2017.04.003Gritsenko OV, Chumakova GA, Ponasenko AV, et al. Some molecular genetic risk factors for myocardial fibrosis (Literature review). The Siberian Journal of Clinical and Experimental Medicine. 2022;37(3):56-64. Russian. DOI: https://doi.org/10.29001/2073-8552-2022-37-3-56-64Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases. International Journal of Molecular Sciences. 2020;21(24):9739. DOI: https://doi.org/10.3390/ijms21249739Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Advances in Pharmacology. 2018;81:241-330. DOI: https://doi.org/10.1016/bs.apha.2017.08.002Zouridakis E, Avanzas P, Arroyo‑Espliguero R, et al. Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris. Circulation. 2004;110(13):1747-1753. DOI: https://doi.org/10.1161/01.CIR.0000142664.18739.92Pecherina TB, Kashtalap VV, Gruzdeva OV, et al. Dynamics and correlation of matrix metalloproteinases in serum and glycemic status indices in patients with ST-elevation myocardial infarction, and type 2 diabetes mellitus. RMJ. Medical Review. 2019;3(6):17-22. Russian.Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. Russian. DOI: https://doi.org/10.15829/29/1560-4071-2020-4076McDonagh T, Metra M. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2023;28(1):5168. Russian. DOI: https://doi.org/10.15829/1560-4071-2023-5168Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. Nucleic Acids Research. 2016;44(D1):D877-D881. DOI: https://doi.org/10.1093/nar/gkv1340Sol&eacute; X, Guin&oacute; E, Valls J, et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22(15):1928-1929. DOI: https://doi.org/10.1093/bioinformatics/btl268Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. American Journal of Human Genetics. 2001;69(1):138-147. DOI: https://doi.org/10.1086/321276Hassanzadeh-Makoui R, Razi B, Aslani S, et al. The association between Matrix Metallo-proteinases-9 (MMP-9) gene family polymorphisms and risk of Coronary Artery Disease (CAD): a systematic review and meta-analysis. BMC Cardiovascular Disorders. 2020;20:232. DOI: https://doi.org/10.1186/s12872-020-01510-4Frąk W, Wojtasińska A, Lisińska W, et al. Pathophysiology of Cardiovascular Diseases: New Insights into Molecular Mechanisms of Atherosclerosis, Arterial Hypertension, and Coronary Artery Disease. Biomedicines. 2022;10(8):1938. DOI: https://doi.org/10.3390/biomedicines10081938Qintao C, Yan L, Changhong D, et al. Genetic polymorphism of matrix metalloproteinase-1 and coronary artery disease susceptibility: a case-control study in a Han Chinese population. Genetic Testing and Molecular Biomarkers. 2014;18(12):826-831. DOI: https://doi.org/10.1089/gtmb.2014.0222Kato K, Tokuda Y, Inagaki N, et al. Association of a matrix metallopeptidase 1 gene polymorphism with long-term outcome of thoracic aortic aneurysm. International Journal of Molecular Medicine. 2012;29(1):125-132. DOI: https://doi.org/10.3892/ijmm.2011.804Guizani I, Zidi W, Zayani Y, et al. Matrix metalloproteinase-3 predicts clinical cardiovascular outcomes in patients with coronary artery disease: a 5&nbsp;years cohort study. Molecular Biology Reports. 2019;46(5):4699-4707. DOI: https://doi.org/10.1007/s11033-019-04914-4Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circulation Research. 2003;92(8):827-839. DOI: https://doi.org/10.1161/01.RES.0000070112.80711.3DP&ouml;ll&auml;nen PJ, Lehtim&auml;ki T, Ilveskoski E, et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis. 2002;164(2):329-335. DOI: https://doi.org/10.1016/S0021-9150(02)00107-7Guizani I, Zidi W, Zayani Y, et al. Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study. Molecular Biology Reports. 2022;49:9171-9179. DOI: https://doi.org/10.1007/s11033-022-07742-1Cho MH, McDonald MLN, Zhou X, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. The Lancet Respiratory Medicine.&nbsp;2014;2(3):214-225. DOI: https://doi.org/10.1016/S2213-2600(14)70002-5Goncharova IA, Koroleva YA, Sleptsov AA, et al. Genetic Structure of Susceptibility to Cardiovascular Continuum Comorbidity. Russian Journal of Genetics. 2022;58(10):1245-1256. DOI: https://doi.org/10.1134/S1022795422100039Zhang FX, Sun DP, Guan N,&nbsp;et al. Association between&minus; 1562C&gt; T polymorphism in the promoter region of matrix metalloproteinase-9 and coronary artery disease: a meta-analysis. Genetic Testing and Molecular Biomarkers. 2014;18(2):98-105. DOI: https://doi.org/10.1089/gtmb.2013.0369Li YY, Yang XX, Zhou YH, et al. Matrix metalloproteinase-9 gene-1562C&gt; T gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis of 5468 subjects. Frontiers in Physiology. 2016;7:212. DOI: https://doi.org/10.3389/fphys.2016.00212Ben Braiek A, Chahed H, Dumont F, et al. Identification of biomarker panels as predictors of severity in coronary artery disease. Journal of Cellular and Molecular Medicine. 2021;25(3):1518-1530. DOI: https://doi.org/10.1111/jcmm.16244Sheikhvatan M, Boroumand MA, Behmanesh M, et al. Association of R279Q and C1562T polymorphisms of matrix metalloproteinase 9 gene and increased risk for myocardial infarction in patients with premature coronary artery disease. Journal of Clinical Laboratory Analysis. 2018;32(1):e22218. DOI: https://doi.org/10.1002/jcla.22218Opstad TB, Pettersen AAR, Weiss TW, et al. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clinica Chimica Acta. 2012;413(1-2):113-120. DOI: https://doi.org/10.1016/j.cca.2011.09.004Guo T, Hao H, Zhou L, et al. Association of SNPs in the TIMP-2 gene and large artery atherosclerotic stroke in southern Chinese Han population. Oncotarget. 2018;9(4):4698-4706. DOI: https://doi.org/10.18632/oncotarget.23473Wang K, Wang G, Huang S, et al. Association between TIMP-2 gene polymorphism and breast cancer in Han Chinese women. BMC Cancer. 2019;19:446. DOI: https://doi.org/10.1186/s12885-019-5655-8de Freitas IA, de Alcantara Lima N, da Silva GBJr, et al. Novel biomarkers in the prognosis of patients with atherosclerotic coronary artery disease. Revista Portuguesa de Cardiologia. 2020;39(11):667-672. DOI: https://doi.org/10.1016/j.repce.2020.05.016Givvimani S, Kundu S, Narayanan N, et al. TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure. Archives of Physiology and Biochemistry. 2013;119(2):65-74. DOI: https://doi.org/10.3109/13813455.2012.755548